Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study of PEP02, Irinotecan or Docetaxel as a Second Line Therapy in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

NCT00813072 is registered in ClinicalTrials.gov with PharmaEngine as lead sponsor.

NCT NCT00813072
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00813072 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study of PEP02, Irinotecan or Docetaxel as a Second Line Therapy in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Lead sponsor
PharmaEngine
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2007
Completion date
December 31, 2010
Enrollment
135 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal neoplasms, stomach neoplasms